Last reviewed · How we verify
Use of insulin glargine twice daily
Use of insulin glargine twice daily is a Small molecule drug developed by Eastern Virginia Medical School. It is currently FDA-approved.
Insulin glargine, marketed for twice-daily use, is developed by Eastern Virginia Medical School and holds a position in the diabetes management market. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Use of insulin glargine twice daily |
|---|---|
| Sponsor | Eastern Virginia Medical School |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management (PHASE4)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy (PHASE3)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PHASE3)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Use of insulin glargine twice daily CI brief — competitive landscape report
- Use of insulin glargine twice daily updates RSS · CI watch RSS
- Eastern Virginia Medical School portfolio CI